gemcitabine has been researched along with ew-7197 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YJ; Han, BS; Hong, SS; Jung, KH; Kim, DK; Kim, SE; Ko, S; Lee, JE; Lee, P; Lee, YJ; Lim, JH; Park, MS; Ryu, JK; Shim, S; Yoon, YC | 1 |
1 other study(ies) available for gemcitabine and ew-7197
| Article | Year |
|---|---|
Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Transforming Growth Factor beta | 2023 |